Beyond fragments.
Into single-cell tumor biology.
An integrated assay combining live single-cell CTC multi-omics with matched ctDNA—from a single blood draw.
The product
What is
OncoIncytes ® ?
OncoIncytes ® is a Cell Biopsy ® assay from 1Cell.Ai that captures living tumor cells from a blood draw, making tumor biology accessible to multi-omic study.
By combining live circulating tumor cells with matched ctDNA, OncoIncytes enables researchers to investigate genomic, transcriptomic and protein biology at single- cell resolution.
2,400+
Samples processed
Across studies in the US, Europe and India.
85%
CTC positivity rate
Across diagnosed patients, stage II–IV, in eight cancer types.
~100%
Metastatic capture rate
CTCs recovered in effectively every metastatic sample analyzed.
20+
Targets from a single cell
Quantitative protein expression across ADC and TCE targets.
WHY IT MATTERS
What Cell-Level Biology Makes Possible
01
Beyond the Bulk Signal
ctDNA gives population averages. OncoIncytes interrogates real, intact tumor cells — capturing cellular biology that fragment-based assays cannot access.
02
Early Resistance Mapping
Detect resistant subclones before clinical progression, enabling rational adaptive trial design and preemptive combination strategies.
03
Minority Subclone Detection
We directly visualize subclone architecture — the minority populations driving acquired resistance before they become clinically dominant.
04
No-Signal Patient Recovery
In low-shedding tumors where ctDNA returns empty, OncoIncytes recovers actionable biology from CTCs — closing the detection gap.
Why OncoIncytes®
Five Things That Make It Different
Together, these capabilities provide a more complete view of tumor biology than population-level analysis alone.
01
Live CTCs
Viable tumor cells, captured intact from blood.
02
True Single-Cell Resolution
Cell by cell, not an averaged population signal.
03
DNA + RNA + Protein
Three molecular layers from the same cell.
04
Matched ctDNA
Cell-free context from the same blood draw.
05
Longitudinal Analysis
Repeatable over time to follow tumor evolution.
Tumors are more than a single molecular signal. Reveal the biology, one cell at a time.
How It Works
From Blood Draw to Single-Cell Multi-Omics
One blood draw yields both live circulating tumor cells and matched ctDNA, profiled across DNA, RNA and protein and analyzed together.
01
Blood draw
2 × 10 ml peripheral blood. Non-invasive, longitudinally repeatable.
CTC capture & ctDNA
Patented live-cell enrichment. Parallel ctDNA extraction and hybridization.
Single-cell multi-omics
1,080-gene panel DNA. RNA gene expression. Protein via immunofluorescence.
AI analytics
Integrated multi-omic analysis. Actionable biomarker insights delivered.
Product Video
OncoIncytes® Assay Overview
Live circulating tumor cell capture and single-cell multi-omic profiling, from blood draw to integrated analysis.
EVIDENCE
Validated Capture Performance
Consistent high capture rates across tumor types, enabling reliable downstream multi-omic profiling.
Patent US20240159764A1 · AACR 2024 #24-A-4367
* % of samples with ≥ 3 CTCs captured
| Cancer Type | N | CTC Positive | Positivity Rate* |
|---|---|---|---|
| Cancer TypeLung | N1,196 | CTC Positive1,002 | Positivity Rate*83.8% |
| Cancer TypeBreast | N251 | CTC Positive196 | Positivity Rate*78.1% |
| Cancer TypePancreas | N115 | CTC Positive106 | Positivity Rate*92.2% |
| Cancer TypeColorectal | N192 | CTC Positive155 | Positivity Rate*80.7% |
| Cancer TypeProstate | N29 | CTC Positive25 | Positivity Rate*86.2% |
| Cancer TypeLiver | N33 | CTC Positive33 | Positivity Rate*100% |
CLINICAL DATA
Kaplan–Meier Overall Survival By Mutation Signature
OncoIncytes ® detects bypass mutations in single circulating tumor cells at baseline—capturing private, sub-clonal variants invisible to ctDNA and enabling earlier resistance profiling.
Patients with bypass pathway mutations have dramatically worse overall survival, indicating a 4× higher risk of death compared to hotspot-only carriers.
Key finding
Baseline detection of EGFR bypass pathway mutations in sCTC predicts early TKI resistance and significantly reduced overall survival— outperforming ctDNA alone.
Your ADC Can't Hit What It Can't See
OncoIncytes provides the cell-level antigen visibility and resistance insight that ctDNA-only platforms structurally cannot deliver — enabling smarter target selection, sharper trial enrollment, and earlier signals on resistance.
One Assay · Three Omic Layers · Complete Target Visibility
Bulk analysis hides resistant and evolving clones. We reveal them.
Cell-level biology for more confident therapeutic decisions—beyond fragment-based signals.
COMPETITIVE DIFFERENTIATION
Why OncoIncytes® Stands Apart
| Capability | OncoInCytes®Cell Biopsy® Platform | Affinity-Based Platforms |
Size-Based Platforms |
|---|---|---|---|
| CapabilityCapture Efficiency | OncoInCytes®Cell Biopsy® Platform80–100% | Affinity-Based Platforms20–65% | Size-Based Platforms42–70% |
| CapabilityCell Viability | OncoInCytes®Cell Biopsy® PlatformLive | Affinity-Based PlatformsFixed only | Size-Based PlatformsLive |
| CapabilitySingle-Cell DNA | OncoInCytes®Cell Biopsy® PlatformYes | Affinity-Based PlatformsNo | Size-Based PlatformsNo |
| CapabilitySingle-Cell RNA | OncoInCytes®Cell Biopsy® PlatformYes | Affinity-Based PlatformsNo | Size-Based PlatformsNo |
| CapabilitySingle-Cell Protein | OncoInCytes®Cell Biopsy® PlatformYes | Affinity-Based PlatformsYes | Size-Based PlatformsYes |
| CapabilityctDNA (Matched) | OncoInCytes®Cell Biopsy® PlatformYes | Affinity-Based PlatformsYes | Size-Based PlatformsNo |
| CapabilityIntra-Tumor Heterogeneity (DNA, RNA) | OncoInCytes®Cell Biopsy® PlatformYes | Affinity-Based PlatformsNo | Size-Based PlatformsNo |
| CapabilityAI-Powered Multi-Omic Analytics* | OncoInCytes®Cell Biopsy® PlatformYes | Affinity-Based PlatformsNo | Size-Based PlatformsNo |
* AI-driven integration of genomic, transcriptomic, and protein data to identify actionable biomarkers and resistance pathways.
APPLICATIONS
Built for Precision Oncology Research
01
Biopharma
Biomarker & therapeutic development
Characterize targets, biomarkers and tumor biology to support therapeutic research.
02
Translational Research
Molecular discovery to clinical investigation
Connect cell-resolved molecular data with translational research programs.
03
Target Validation
Fresh patient samples, real target expression
We procure fresh blood samples from cancer patients and analyze target expression at single-cell resolution.
04
Biomarker & Companion Diagnostic Development
Support biomarker and targeted therapy research programs.
Generate molecular evidence to support research programs for targeted therapies.
KEY USE CASES FOR ADC & BIOMARKER PROGRAMS
Your ADC can’t hit
what it can’t see.
OncoIncytes provides the cell-level antigen visibility and resistance insight that ctDNA-only platforms structurally cannot deliver— enabling smarter target selection, sharper trial enrollment and earlier signals on resistance.
01
ADC target antigen validation
Quantify surface antigen expression (HER2, TROP2, HER3) at single-cell resolution on live CTCs. Identify heterogeneous expressors and subpopulations predicting bystander effect dependence.
02
Patient stratification & trial enrichment
Go beyond IHC thresholds. Use real-time CTC multi-omics to enrich trial arms with true antigen-high expressors and flag subclonal antigen loss before enrollment.
03
Resistance mechanism profiling
Characterize resistance via antigen downregulation, internalization defects, or payload efflux longitudinally from blood — before progression on imaging.
04
Longitudinal monitoring
Track on-treatment evolution of target antigen and transcriptomic response with serial blood draws to guide adaptive dosing and combination strategies.
THE TECHNOLOGY
Powered by Cell Biopsy®
The technology foundation behind OncoIncytes®.
THE INTELLIGENCE
Connected to iCore™
The intelligence layer for integrating and
analyzing OncoIncytes® data.
Get Started
See Cancer Through Every Cell.
Explore what OncoIncytes® can enable for biomarker discovery, drug development and translational oncology research.
Access OncoIncytes Case Studies
Fill in your details to download the case studies.
Access the OncoIncytes Brochure
Fill in your details to explore OncoIncytes testing insights and download the brochure.